D. Kim

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia

S. Mustjoki, B. Druker, J. Cortes, 2019, Leukemia.

The clonal origins of leukemic progression of myelodysplasia

S. Y. Kim, Marc S. Tyndel, Zhaolei Zhang, 2016, Leukemia.

Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy.

L. Busque, S. Cerquozzi, A. Xenocostas, 2023, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

S. Voloshin, M. Mauro, N. Chaudhri, 2021 .

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

S. Kapoor, M. Mauro, A. Hochhaus, 2023, Leukemia.

In Vitro Evidence of Double Blockade of Asciminib with Reduced Dose of ATP-Binding Pocket Inhibitors in the Treatment of Chronic Myeloid Leukemia Harboring ABL1 Kinase Domain Mutation

Jong-Won Kim, TaeHyung Kim, H. Jang, 2022, Blood.

A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs.

J. Cortes, M. Mauro, A. Hochhaus, 2021, Blood.